Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KER-050 in lower-risk myelodysplastic syndromes
ACTRN12620000696998Phase 2Recruiting
- Sponsor
- Keros Therapeutics
- Start
- Aug 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of elritercept in myelodysplastic syndrome (MDS) (2 arms), sponsored by Keros Therapeutics. Primary endpoints: Safety and tolerability of KER-050 and Progression to higher-risk MDS or acute myeloid leukemia. Started Aug 2020; status: recruiting.
02
Drugs
elritercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ACTRN12620000696998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000696998.